Influenza Vaccine Composition

The periodic replacement of virus strains contained in influenza vaccine is necessary because of the constant evolution of influenza viruses, which can change their antigenic and genetic characteristics. The World Health Organization (WHO) recommends the following influenza vaccine composition information.

Seasonal Influenza Risk Groups

The WHO recommends that trivalent vaccines for use in the 2023-2024 northern hemisphere influenza season contain the following:

Egg-based vaccines

Cell culture- or recombinant-based vaccines

For quadrivalent egg- or cell culture-based or recombinant vaccines for use in the 2023-2024 northern hemisphere influenza season, the WHO recommends inclusion of the following as the B/Yamagata lineage component:

Development and production of influenza vaccines, planning for their supplies and use as well as provision of other respective health care resources are essential components of a comprehensive seasonal and pandemic influenza response. 2

Southern Hemisphere 2024

The WHO recommends that trivalent vaccines for use in the 2024 southern hemisphere influenza season contain the following:

Egg-based vaccines

Cell culture- or recombinant-based vaccines

For quadrivalent egg- or cell culture-based or recombinant vaccines for use in 2024 southern hemisphere influenza season, the WHO recommends inclusion of the following B/Yamagata lineage component:

Development and production of influenza vaccines, planning for their supplies and use as well as provision of other respective health care resources are essential components of a comprehensive seasonal and pandemic influenza response. 2

Subscribe to our Publications

To subscribe to the APACI Newsletter and APACI Media Bulletin

Subscribe